DekaBank Deutsche Girozentrale Sells 22,320 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

DekaBank Deutsche Girozentrale cut its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 74.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,500 shares of the company's stock after selling 22,320 shares during the period. DekaBank Deutsche Girozentrale's holdings in Inspire Medical Systems were worth $1,508,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in INSP. FMR LLC raised its position in shares of Inspire Medical Systems by 130.1% in the 3rd quarter. FMR LLC now owns 2,471,464 shares of the company's stock worth $490,437,000 after acquiring an additional 1,397,510 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Inspire Medical Systems by 72.8% in the 3rd quarter. Wellington Management Group LLP now owns 976,972 shares of the company's stock worth $193,870,000 after acquiring an additional 411,480 shares in the last quarter. Norges Bank acquired a new stake in shares of Inspire Medical Systems in the 4th quarter valued at about $65,929,000. Envestnet Asset Management Inc. grew its stake in shares of Inspire Medical Systems by 1,117.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 231,421 shares of the company's stock valued at $4,586,000 after buying an additional 212,406 shares during the period. Finally, 1832 Asset Management L.P. acquired a new stake in shares of Inspire Medical Systems in the 1st quarter valued at about $43,186,000. 94.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Stifel Nicolaus restated a "hold" rating and issued a $210.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, January 2nd. KeyCorp assumed coverage on Inspire Medical Systems in a research note on Tuesday, February 6th. They issued an "overweight" rating and a $278.00 target price for the company. Jefferies Financial Group assumed coverage on Inspire Medical Systems in a research note on Friday, January 19th. They issued a "buy" rating and a $245.00 target price for the company. Morgan Stanley began coverage on Inspire Medical Systems in a research note on Tuesday, March 19th. They issued an "overweight" rating and a $250.00 target price for the company. Finally, Mizuho reiterated a "buy" rating and set a $250.00 price target on shares of Inspire Medical Systems in a research note on Wednesday, March 27th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $271.29.

Inspire Medical Systems Trading Down 3.7 %

Shares of NYSE:INSP traded down $8.60 during mid-day trading on Monday, reaching $223.14. The company had a trading volume of 267,976 shares, compared to its average volume of 515,560. The firm has a market cap of $6.76 billion, a price-to-earnings ratio of -301.19 and a beta of 1.37. The company's 50-day moving average price is $201.18 and its 200-day moving average price is $182.62. Inspire Medical Systems, Inc. has a one year low of $123.27 and a one year high of $330.00.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.53. Inspire Medical Systems had a negative net margin of 3.39% and a negative return on equity of 3.93%. The firm had revenue of $192.51 million during the quarter, compared to analyst estimates of $186.75 million. During the same period in the previous year, the business earned $0.10 EPS. The business's revenue for the quarter was up 39.6% on a year-over-year basis. On average, research analysts anticipate that Inspire Medical Systems, Inc. will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Inspire Medical Systems news, insider Randy Ban sold 3,060 shares of the business's stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $182.01, for a total value of $556,950.60. Following the completion of the sale, the insider now directly owns 3,029 shares of the company's stock, valued at $551,308.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Inspire Medical Systems news, insider Randy Ban sold 3,060 shares of the business's stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $182.01, for a total value of $556,950.60. Following the completion of the sale, the insider now directly owns 3,029 shares of the company's stock, valued at $551,308.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerry C. Griffin sold 554 shares of the business's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $198.05, for a total transaction of $109,719.70. Following the completion of the sale, the director now directly owns 9,744 shares of the company's stock, valued at $1,929,799.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,371 shares of company stock worth $12,213,828. Corporate insiders own 4.10% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.